IT-DEX treatment is at least as effective as IV-DEX treatment for SSNHL patients with diabetes.

Patients with vertigo caused by psychological problems have increased in recent years. It has been reported that many outpatients with vertigo also suff er from depression. Selective serotonin reuptake inhibitors are widely used for the treatment of depression because of their effi cacy and relatively favorable side-eff ects profi le compared to those of tricyclic antidepressants. We used Paroxetine to treat patients with vertigo who were diagnosed with depression by self-rating questionnaires for depression (SRQ-D). Twenty-six patients experienced relief a er taking Paroxetine. Fi een of them were relieved of their vertigo symptoms, 8 were improved, one was not changed, and two were worse. SRQ-D scores were compared between the day of commencement and the day a er 4 weeks. Fi een patients were normalized. Side eff ects occurred in seven patients; nausea in fi ve and sleepiness in two. e average duration of taking the medicine was 24.4 weeks. Since Paroxetine showed benefi cial clinical eff ects for patients with vertigo, this medicine might be useful for vertiginous patients with depression.

No abstract